Alkermes settles with Amneal over opioid dependence treatment

31-07-2019

Sarah Morgan

Alkermes settles with Amneal over opioid dependence treatment

Biopharmaceutical company Alkermes has entered into a settlement and licence agreement with generic maker Amneal Pharmaceuticals to resolve an inter partes review (IPR).


Alkermes, Amneal, opioid dependence, inter partes review, IPR, PTAB, settlement, generics, Vivitrol

LSIPR